text_1: Cancers that initially benefit from epidermal growth factor receptor targeted therapies later become refractory through several mechanisms.
text_2: An increasing understanding of the number and complexity of resistance mechanisms highlights the Herculean challenge of killing tumors that are resistant to EGFR inhibitors.